Leerink Partnrs Comments on MannKind Co.’s Q1 2025 Earnings (NASDAQ:MNKD)

MannKind Co. (NASDAQ:MNKD) – Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of MannKind in a report released on Monday, September 9th. Leerink Partnrs analyst F. Khurshid anticipates that the biopharmaceutical company will earn $0.03 per share for the quarter. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for MannKind’s current full-year earnings is $0.11 per share. Leerink Partnrs also issued estimates for MannKind’s Q2 2025 earnings at $0.03 EPS, Q3 2025 earnings at $0.04 EPS and Q4 2025 earnings at $0.04 EPS.

A number of other research analysts also recently commented on MNKD. Rodman & Renshaw started coverage on MannKind in a report on Thursday, June 13th. They set a “buy” rating and a $8.00 target price on the stock. Oppenheimer lifted their price objective on shares of MannKind from $10.00 to $12.00 and gave the stock an “outperform” rating in a report on Wednesday, August 28th. Finally, Leerink Partners initiated coverage on shares of MannKind in a report on Monday. They set an “outperform” rating and a $8.00 target price on the stock. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, MannKind presently has an average rating of “Buy” and an average price target of $8.67.

MannKind Stock Performance

NASDAQ:MNKD opened at $6.13 on Tuesday. The company has a market capitalization of $1.69 billion, a price-to-earnings ratio of 204.40 and a beta of 1.32. MannKind has a one year low of $3.17 and a one year high of $6.44. The stock has a 50-day simple moving average of $5.60 and a 200 day simple moving average of $4.93.

MannKind (NASDAQ:MNKD) last announced its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.04. The company had revenue of $72.39 million during the quarter, compared to analyst estimates of $64.81 million. MannKind had a net margin of 4.73% and a negative return on equity of 11.97%. The firm’s revenue for the quarter was up 48.9% compared to the same quarter last year. During the same period last year, the business earned ($0.02) EPS.

Hedge Funds Weigh In On MannKind

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Meeder Asset Management Inc. acquired a new stake in shares of MannKind in the 2nd quarter worth approximately $55,000. 9258 Wealth Management LLC acquired a new stake in MannKind in the first quarter worth approximately $51,000. Brookstone Capital Management bought a new position in MannKind during the 2nd quarter valued at $61,000. Renaissance Technologies LLC acquired a new position in shares of MannKind during the 2nd quarter valued at $67,000. Finally, EntryPoint Capital LLC raised its stake in shares of MannKind by 60.9% in the 1st quarter. EntryPoint Capital LLC now owns 23,809 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 9,008 shares in the last quarter. Institutional investors own 49.55% of the company’s stock.

Insider Buying and Selling at MannKind

In related news, insider Stuart A. Tross sold 25,000 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $6.26, for a total value of $156,500.00. Following the sale, the insider now owns 1,022,191 shares of the company’s stock, valued at approximately $6,398,915.66. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other MannKind news, insider Stuart A. Tross sold 80,000 shares of the business’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $6.33, for a total transaction of $506,400.00. Following the completion of the transaction, the insider now owns 1,047,191 shares in the company, valued at approximately $6,628,719.03. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Stuart A. Tross sold 25,000 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $6.26, for a total value of $156,500.00. Following the transaction, the insider now directly owns 1,022,191 shares in the company, valued at $6,398,915.66. The disclosure for this sale can be found here. Over the last three months, insiders have sold 197,997 shares of company stock worth $1,245,912. 3.00% of the stock is owned by insiders.

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.